Icotrokinra (Icotyde®): Mechanism, Dosage, Monitoring, Side Effects & Full Prescribing Guide
A structured, evidence-based clinical reference for the first targeted oral peptide IL-23 receptor antagonist approved for moderate-to-severe plaque psoriasis.
- Brand Name
- Icotyde®
- Generic Name
- Icotrokinra
- Drug Class
- IL-23 Receptor Antagonist
- Manufacturer
- Janssen Biotech / J&J
- Dosage Form
- 200 mg film-coated tablet
- Route
- Oral — once daily
- FDA Approval Date
- March 17, 2026
- Molecular Class
- 13-amino-acid cyclic peptide
1. Mechanism of Action
Icotrokinra is a first-in-class targeted oral cyclic peptide that selectively binds the interleukin-23 receptor (IL-23R) with picomolar affinity. Unlike injectable IL-23 monoclonal antibodies — such as guselkumab, risankizumab, or tildrakizumab — which neutralize the IL-23 cytokine in circulation, icotrokinra acts directly at the receptor level on the surface of immune cells. This provides a more proximal blockade of the inflammatory signaling cascade while delivering the convenience of a daily oral pill.
The IL-23/Th17 axis is the central driver of chronic inflammation in plaque psoriasis. IL-23 promotes the differentiation, expansion, and survival of pathogenic Th17 cells, which secrete IL-17 and other cytokines that drive epidermal hyperproliferation and plaque formation. By blocking the receptor, icotrokinra interrupts this loop at its root.
2. Approved Indications
Treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients ≥ 12 years of age who weigh ≥ 40 kg (88 lb) and are candidates for systemic therapy or phototherapy.
Pipeline / Investigational Uses
Icotrokinra is under active clinical evaluation for several additional IL-23–mediated inflammatory conditions:
| Condition | Development Stage | Key Data |
|---|---|---|
| Psoriatic Arthritis | Phase 3 (biologic-naïve & biologic-experienced) | Studies ongoing |
| Ulcerative Colitis | Phase 2b (ANTHEM-UC) | Primary endpoint met; highest dose achieved 63.5% clinical response at week 12 |
| Crohn’s Disease | Under evaluation | Studies in moderately-to-severely active disease |
3. Dosage & Administration
| Parameter | Recommendation |
|---|---|
| Recommended dose | 200 mg orally, once daily |
| When to take | Upon waking, on an empty stomach, with water |
| Food restriction | Wait ≥ 30 minutes before eating. A high-fat meal reduces AUC by 43% and Cmax by 59%. |
| Swallowing | Swallow whole — do not crush, split, or chew |
| Alternative for dysphagia | Tablet may be dispersed in water |
| Tablet description | Yellowish-orange to yellowish-brown, oval, film-coated; debossed “200” / “JNJ” |
| Dose titration | None required — 200 mg is both starting and maintenance dose |
| Missed dose | Take as soon as remembered (on empty stomach); resume normal schedule next morning |
| Storage | 20°C–25°C (68°F–77°F) in original bottle with desiccant; protect from moisture |
No induction phase, no weight-based adjustment (for patients ≥ 40 kg), and no dose escalation. Simplicity of dosing is one of icotrokinra’s key advantages over injectable biologics and even some other oral agents.
4. Baseline & Follow-Up Monitoring
Pre-Treatment (Baseline)
| Assessment | Details & Rationale |
|---|---|
| TB screening | Evaluate for latent/active TB based on clinical judgment. Initiate anti-TB therapy if positive before starting icotrokinra. |
| Active infection screen | Do not initiate if a clinically important active infection is present. Defer until resolved or adequately treated. |
| Vaccination status | Complete all age-appropriate immunizations before treatment. Live vaccines are contraindicated during therapy. |
| Hepatitis B/C | Screen per standard immunomodulatory therapy protocols. |
| Renal function (eGFR) | Icotrokinra AUC increases 2.47× in moderate and 2.78× in severe renal impairment — assess baseline kidney function. |
| Pregnancy test | Verify in females of childbearing potential. |
| Disease severity scores | Document baseline PASI, IGA, BSA, and DLQI for treatment response tracking. |
Ongoing Follow-Up
| Parameter | Recommended Schedule |
|---|---|
| Infection surveillance | Every visit. Counsel patients to report fever, cough, breathing difficulty, chills, night sweats, or new skin changes. |
| TB monitoring | Watch for signs/symptoms of active TB during and after treatment. |
| Efficacy assessment | PASI / IGA at weeks 16 and 24, then periodically. Consider treatment modification if inadequate response by week 16–24. |
| Renal function | Periodic monitoring in patients with moderate-to-severe renal impairment. |
5. Side Effects & Adverse Reactions
Icotrokinra demonstrated a placebo-like safety profile in the ICONIC Phase 3 program. Through 16 weeks, the overall proportion of patients experiencing adverse events was 49% — identical in both the icotrokinra and placebo groups. No new safety signals emerged through 52 weeks of continuous treatment.
Common Adverse Reactions (≥ 1%)
| Adverse Reaction | Incidence (Icotrokinra) | Context |
|---|---|---|
| Headache | 4.1% | Most common; generally mild and transient |
| Nausea | 1.2% | Usually self-limiting |
| Cough | 1.2% | — |
| Fungal infections | 1.1% | Consistent with immunomodulation |
| Fatigue | 1.0% | — |
Infection Risk
In 16-week controlled trials, serious infection rates were 0.2% with icotrokinra versus 0.4% with placebo. The most common infections overall (both groups) were nasopharyngitis and upper respiratory tract infections. No clinically significant QTc prolongation was observed even at 5× the recommended dose.
6. Precautions & Warnings
Icotrokinra may lower the body’s ability to fight infections. Do not start treatment in patients with any clinically important active infection. If a serious infection develops and does not respond to standard therapy, discontinue icotrokinra until the infection resolves. Use caution in patients with chronic or recurrent infections — weigh risks and benefits before prescribing.
Evaluate for TB infection prior to initiating therapy. If latent or active TB is identified, begin appropriate anti-TB treatment before starting icotrokinra. Monitor for TB signs and symptoms during and after treatment.
Avoid live vaccines (e.g., MMR, varicella, live-attenuated influenza) during icotrokinra treatment. Complete all age-appropriate vaccinations before initiating therapy. Non-live (inactivated) vaccines may be given during treatment.
Special Populations
| Population | Guidance |
|---|---|
| Renal impairment (mild) | No dose adjustment needed. |
| Renal impairment (moderate/severe) | AUC increases 2.47–2.78×. Use with caution; no formal dose recommendation — individualize based on clinical judgment. |
| Hepatic impairment | Icotrokinra undergoes peptide catabolism, not hepatic CYP metabolism. Formal studies not required. |
| Pediatric (≥ 12 yr, ≥ 40 kg) | Approved. Studied in ICONIC-LEAD and ICONIC-TOTAL. |
| Pediatric (< 12 yr or < 40 kg) | Safety and efficacy not established. |
| Geriatric (≥ 65 yr) | No overall differences observed in trials, though elderly patient numbers were limited. |
7. Drug Interactions
No clinically significant drug–drug interactions have been identified. Because icotrokinra is a peptide degraded by normal catabolism (not CYP-mediated metabolism), the likelihood of traditional pharmacokinetic drug interactions is very low.
While CYP interactions are unlikely, patients should still report all medications — including OTC products, herbals, and supplements — to their prescriber. The absence of CYP interaction does not rule out pharmacodynamic interactions when combining immunomodulatory agents.
8. Pregnancy & Lactation
Pregnancy
Available data on icotrokinra use during human pregnancy are insufficient to evaluate the risk of major birth defects, miscarriage, or other adverse maternal/fetal outcomes. The decision to use during pregnancy should involve careful risk–benefit assessment by the prescriber and the patient.
Animal Reproductive Toxicology
| Species / Study | Dose Range | Finding |
|---|---|---|
| Rats — embryo-fetal | 70–1000 mg/kg/day | No maternal or embryo-fetal toxicity at doses up to 1000 mg/kg/day (297× MRHD by AUC) |
| Rabbits — embryo-fetal | 50–500 mg/kg/day | At 500 mg/kg/day (157× MRHD): maternal weight loss, low food intake, late pregnancy loss, increased fetal fused ribs. No effects at lower doses. |
| Rats — pre/postnatal | 20–200 mg/kg/day | No maternal or developmental toxicity up to 200 mg/kg/day (127× MRHD) |
A pregnancy safety study is available. If a patient becomes pregnant while on icotrokinra, healthcare providers can report the exposure by calling 1-800-526-7736 or visiting www.ICOTYDE.com.
Lactation
There are no human data on whether icotrokinra passes into breast milk, its effects on the breastfed infant, or its impact on milk production. In animal studies, the drug was detected in the plasma of nursing rat pups, suggesting likely transfer. Clinicians should consider the developmental and health benefits of breastfeeding alongside the mother’s treatment needs and any potential risk to the infant.
9. Maintenance Dosage & Long-Term Use
The maintenance dose is identical to the starting dose: 200 mg orally once daily. There is no step-down, taper, or interval extension. Treatment should be continued as long as clinical benefit is maintained.
Long-term safety and efficacy data from the ICONIC program through at least 52 weeks showed sustained skin clearance with no new safety signals emerging. Randomized withdrawal analyses are underway to evaluate durability of response after treatment discontinuation — results are expected to be presented at upcoming medical meetings.
| Long-Term Endpoint | Data |
|---|---|
| Efficacy maintenance at 52 weeks | Sustained — no loss of response observed in continuous-treatment arms |
| New safety signals at 52 weeks | None identified |
| Withdrawal/durability data | Pending presentation |
10. Clinical Evidence — The ICONIC Program
FDA approval was supported by four pivotal Phase 3 randomized controlled trials enrolling approximately 2,500 patients across adults and adolescents with moderate-to-severe plaque psoriasis.
The first-ever head-to-head trial comparing an oral psoriasis therapy versus an injectable biologic (ustekinumab). This landmark study aims to establish whether the oral peptide approach can match or surpass injectable biologic-level outcomes. Results are anticipated before full commercial launch.
Safety Summary Across All ICONIC Trials
- Adverse event rates with icotrokinra were within 1.1% of placebo through week 16.
- Pooled AE incidence: icotrokinra 49.1% vs placebo 49.2%.
- Serious infection rate: 0.2% (icotrokinra) vs 0.4% (placebo).
- No new safety signals through 52 weeks of continuous treatment.
- Published in The Lancet (2025) and NEJM (2025).
11. Frequently Asked Questions
Is icotrokinra a biologic?
Not in the traditional sense. It is a synthetic 13-amino-acid cyclic peptide, not a monoclonal antibody. However, it delivers biologic-like precision by targeting the IL-23 receptor with picomolar affinity — while being administered as an oral pill rather than an injection.
How quickly does icotrokinra work?
Statistically significant skin clearance was observed as early as week 4 in clinical trials. Primary efficacy endpoints were measured at weeks 16–24, with continued improvement through week 52.
Can I take icotrokinra with food?
No. It must be taken on an empty stomach upon waking, with at least a 30-minute wait before eating. A high-fat meal significantly reduces absorption (43% lower AUC, 59% lower peak levels).
How much does Icotyde cost?
The approximate U.S. retail price is around $8,159 for a 30-day supply. Johnson & Johnson offers the ICOTYDE withMe patient access program providing cost support, a dedicated nurse guide, and educational resources regardless of insurance type.
Can adolescents take icotrokinra?
Yes. It is FDA-approved for patients aged ≥ 12 years weighing ≥ 40 kg. Adolescent efficacy and safety were evaluated directly in the ICONIC-LEAD and ICONIC-TOTAL Phase 3 trials.
Does icotrokinra require blood test monitoring?
There are no mandatory routine lab tests during therapy. However, TB screening before treatment and periodic infection surveillance are recommended. Renal function monitoring is prudent in patients with known moderate-to-severe kidney impairment.
References
- ICOTYDE (icotrokinra) Full Prescribing Information. Janssen Biotech, Inc. March 2026. DailyMed / NLM.
- Bissonnette R, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents (ICONIC-LEAD). N Engl J Med. 2025. PMID: 41191940.
- ICONIC-ADVANCE 1 & 2 Phase 3 Results. The Lancet. 2025.
- Johnson & Johnson Press Release: FDA Approval of ICOTYDE. March 18, 2026.
- ClinicalTrials.gov: NCT06095115 (LEAD), NCT06143878 (ADVANCE 1), NCT06220604 (ADVANCE 2), NCT06095102 (TOTAL).
- Drugs.com. Icotyde FDA Approval History. Accessed March 2026.
- GoodRx. Icotyde Pricing and Information. Accessed March 2026.
- ICOTYDE Medication Guide. Janssen Biotech, Inc. 2026.